Clinical Trial Update: "Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a prime-boost vaccination strategy using a conjugated pneumococcal vaccine with a polysaccharide pneumococcal vaccine in Common Varia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Variable Immunodeficiency

Drugs mentioned

• Conjugated anti-pneumococcal vaccine (conjugated pneumococcal vaccine)
• Polysaccharide anti-pneumococcal vaccine (polysaccharide pneumococcal vaccine)

Snippet

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Conditions: Common Variable Immunodeficiency | Phase 2 | Status: TERMINATED